Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast

[News]

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival and time-to-progression.

More... (http://www.news-medical.net/news/20110520/Bayer-Onyx-to-present-Nexavar-chemotherapy-combination-Phase-2b-trial-data-in-breast-cancer-at-ASCO-2011.aspx)